Tasimelteon for insomnia

A review of ramelteon in the treatment of sleep disorders

(2011) David Neubauer   Neuropsychiatric Disease and Treatment

Low-Dose Doxepin

(2010) Juliane Weber et al.   CNS DRUGS

Investigational melatonin receptor agonists

(2010) Rüdiger Hardeland   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Melatonin agonists and insomnia

(2010) Sally A Ferguson et al.   Expert Review of Neurotherapeutics

New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists

(2010) Ruediger Hardeland   Neuropsychiatric Disease and Treatment

Melatonin: Signaling mechanisms of a pleiotropic agent

(2009) Rüdiger Hardeland   BIOFACTORS

Pharmacology of Ramelteon, a Selective MT1/MT2Receptor Agonist: A Novel Therapeutic Drug for Sleep Disorders

(2009) Masaomi Miyamoto   CNS Neuroscience & Therapeutics

The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia

(2009) Remy Luthringer et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Melatonin and its agonists: an update

(2008) Josephine Arendt et al.   BRITISH JOURNAL OF PSYCHIATRY

Melatonin, hormone of darkness and more – occurrence, control mechanisms, actions and bioactive metabolites

(2008) R. Hardeland   CELLULAR AND MOLECULAR LIFE SCIENCES

Sleep and the epidemic of obesity in children and adults

(2008) Eve Van Cauter et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Prolonged-release melatonin for the treatment of insomnia in patients over 55 years

(2008) Alan Wade et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials

(2008) Shantha MW Rajaratnam et al.   LANCET